vimarsana.com

Latest Breaking News On - Arshadm khanani - Page 3 : vimarsana.com

Opthea Reports Half-Year Financial Results And Business Updates

Opthea Reports Half-Year Financial Results And Business Updates
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

Australia
Melbourne
Victoria
Julie-clark
Frederic-guerard
Silvana-guerci-lena
Arshadm-khanani
Megan-baldwin
Fred-guerard
Fang-li
Peter-lang
Exchange-commission

Opthea Reports Half-Year Financial Results and Business Updates

Enrollment completion of sozinibercept Phase 3 program for wet AMD expected in calendar year Q2 2024 with top-line data mid-CY 2025 Expanded U.S. leadership team with the appointments of Dr..

Australia
Melbourne
Victoria
Arshadm-khanani
Frederic-guerard
Julie-clark
Fang-li
Peter-lang
Megan-baldwin
Fred-guerard
Silvana-guerci-lena
Regulatory-affairs

Oculis Provides Updates at R&D Day on Late-Stage Clinical Trials and Announces Key Leadership Appointments

Completed enrollment in Phase 2b RELIEF trial of Licaminlimab , anti-TNF alpha eye drops in Dry Eye Disease ; topline results expected in Q2 2024Second Phase 3 trial of OCS-01 eye drops in Diabetic.

Virginia
United-states
Massachusetts
Eastern-virginia-medical-school
Paris
France-general
France
Vermont
Boston
Switzerland
American
Sylvia-cheung

Opthea Reports Half-Year Financial Results and Business Updates

Opthea Reports Half-Year Financial Results and Business Updates
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Australia
Melbourne
Victoria
Fred-guerard
Silvana-guerci-lena
Fang-li
Peter-lang
Frederic-guerard
Julie-clark
Megan-baldwin
Arshadm-khanani
Regeneron-pharmaceuticals-inc

Opthea Appoints Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor

Global retina expert joins to support sozinibercept development and launch preparationMELBOURNE, Australia, Feb. 19, 2024 (GLOBE NEWSWIRE) Opthea Limited (ASX:OPT; NASDAQ:OPT, “Opthea”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced the appointment of Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor. An internationally recognized retina specialist and clinical scientist, Dr. Khanani i

University-of-nevada
Nevada
United-states
Australia
Melbourne
Victoria
American
Frederic-guerard
Arshadm-khanani
Rudi-michelson
Macula-society
Opthea-limited

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.